Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Looks Ahead To Complex Product-Specific Guidances

Exploring The US FDA's Upcoming Complex Generic Product-Specific Guidance Lists

Executive Summary

The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

You may also be interested in...



FDA Publishes 69 Product-Specific Guidances

The FDA has issued 69 product-specific guidances for generic drug development, comprising 26 new guidances and 43 revised documents.

Was Coronavirus A Factor In Cipla's Albuterol FDA Approval?

The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.

Was Coronavirus A Factor In US FDA Approval Of Proventil HFA First Generic?

The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel